A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

PHASE2CompletedINTERVENTIONAL
Enrollment

259

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

December 18, 2023

Study Completion Date

January 12, 2024

Conditions
Early Alzheimers DiseaseMild Cognitive Impairment Due to AD
Interventions
DRUG

PQ912

PQ912 50 mg tablets and 150 mg tablets

DRUG

Placebo

Placebo tablets to mimic PQ912 50 mg and 150 mg tablets

Trial Locations (21)

8025

Brain Research Center Zwolle, Zwolle

10450

Charité - Universitätsmedizin Berlin, Berlin

24105

Universitätsklinikum Schleswig-Holstein (UKSH), Klinik für Neurologie, Kiel

39120

Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung, Magdeburg

41009

Unidad de Neurociencias. Hospital Victoria Eugenia, Seville

48149

Universitätsklinikum Münster / Klinik für Allgemeine Neurologie, Münster

48993

Cae Oroitu, Getxo

68165

Institut für Studien zur Psychischen Gesundheit (ISPG), Mannheim

81675

Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie, München

89081

Klinik für Neurologie Universitätsklinikum Ulm, Ulm

Unknown

Sanos Clinics, Ganderup

Sanos Clinics, Herlev

Sanos Clinics, Vejle

Brain Research Center, 's-Hertogenbosch

Brain Research Center, Amsterdam

15-756

Podlaskie Centrum, Bialystok

90-368

SOMED CR, Lodz

92-216

Klinika Psychiatrii Wieku Podeszłego i Zaburzeń Psychotycznych Uniwersytetu Medycznego w Łodzi, Lodz

01-737

SOMED CR, Warsaw

08025

Neurology (Memory Unit) - Hospital de la Santa Creu i Sant Pau, Barcelona

08028

Fundació ACE, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Nordic Bioscience A/S

INDUSTRY

collaborator

Amsterdam UMC, location VUmc

OTHER

lead

Vivoryon Therapeutics N.V.

INDUSTRY

NCT04498650 - A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD | Biotech Hunter | Biotech Hunter